Read our latest updates & insights

On 5 February 2024, Novo Nordisk’s parent company Novo Holdings announced that it will acquire global contract development and manufacture company Catalent for USD $16.5B.  

Novo Holdings will secure 50 global sites in the acquisition and intends to sell three fill-f...

Novo Nordisk settled two lawsuits over counterfeit versions of Ozempic® (semaglutide) and Wegovy® (semaglutide).  The two companies involved, Cosmetic Laser Professionals Med Spa and Nuvida RxWeight Loss are permanently banned from claiming that their products are approved ...

Incyte has announced it has entered into an asset purchase agreement with MorphoSys, giving Incyte exclusive global development and commercialisation rights to tafasitamab, to be marketed in the US as Monjuvi® and outside the US as Minjuvi®.

In a previous agreement, ...

A study published in Medicina, on 4 February 2024, concluded that Rituximab represents an “efficacious and well-tolerated therapeutic option” for the management of Autoimmune Bullous Diseases (AIBD) and warrants consideration in cases of refractory AIBD.  

Regeneron announced that its marketing authorisation application (MAA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM), was accepted for review by the European Medicines Agency (EMA).  The MAA is supported by data from a Phase ...

Shanghai Henlius Biotech announced its phase 1 clinical study for its denosumab biosimilar of HLX14, which met the primary endpoint.
Shanghai Henlius Biotech announced commencement of the study in November 2020.  Organon announceda deal in June 2022 for exclusive glob...

Korea Biomedical Review reported that Samsung Bioepis and Samil Pharmaceutical will co-market SB15, Samsung’s biosimilar of Regeneron’s Eylea® (aflibercept) in Korea.  The agreement intends to utilise Samsung’s R&D capabilities with Samil Pharmaceuticals’ sales and mark...

On 31 January 2024, the US District Court for the Northern District of West Virginia published a redacted version of Judge Thomas Kleeh’s Memorandum Opinion and Order, setting out the detailed reasons for his previous finding that Mylan and Biocon infringed eight claims of ...

Novo Nordisk announced in its 2023 Annual Report that it has increased sales by 31% to DKK 232.3B in 2023, and increased its operating profit by 37% in Danish Kroner.  Key developments outlined in the Report include:

a 51% net profit increase and 49% increase in sh...

Outlook Therapeutics announced that it has dosed the first subject in its clinical trial (NORSE EIGHT) which aims to evaluate the effect of ophthalmic formulation of bevacizumab (ONS-5010), in patients suffering from neovascular age-related macular degeneration (wet AMD).